DE60038503D1 - AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER - Google Patents

AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER

Info

Publication number
DE60038503D1
DE60038503D1 DE60038503T DE60038503T DE60038503D1 DE 60038503 D1 DE60038503 D1 DE 60038503D1 DE 60038503 T DE60038503 T DE 60038503T DE 60038503 T DE60038503 T DE 60038503T DE 60038503 D1 DE60038503 D1 DE 60038503D1
Authority
DE
Germany
Prior art keywords
kappab
antigen
trigger
activation
immune system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038503T
Other languages
English (en)
Other versions
DE60038503T2 (de
Inventor
Brian Foxwell
Marc Feldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Mathilda and Terence Kennedy Institute of Rheumatology Trust
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mathilda and Terence Kennedy Institute of Rheumatology Trust, Kennedy Institute of Rheumotology filed Critical Mathilda and Terence Kennedy Institute of Rheumatology Trust
Publication of DE60038503D1 publication Critical patent/DE60038503D1/de
Application granted granted Critical
Publication of DE60038503T2 publication Critical patent/DE60038503T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/06—Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60038503T 1999-12-24 2000-12-22 AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER Expired - Lifetime DE60038503T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9930616 1999-12-24
GBGB9930616.9A GB9930616D0 (en) 1999-12-24 1999-12-24 Activation and inhibition of the immune system
PCT/GB2000/004925 WO2001047543A2 (en) 1999-12-24 2000-12-22 Activation and inhibition of the immune system

Publications (2)

Publication Number Publication Date
DE60038503D1 true DE60038503D1 (de) 2008-05-15
DE60038503T2 DE60038503T2 (de) 2009-04-30

Family

ID=10867023

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038503T Expired - Lifetime DE60038503T2 (de) 1999-12-24 2000-12-22 AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER

Country Status (12)

Country Link
US (2) US7915009B2 (de)
EP (2) EP1244466B1 (de)
JP (1) JP2003518507A (de)
CN (2) CN1254272C (de)
AT (1) ATE390929T1 (de)
AU (1) AU781496B2 (de)
CA (1) CA2394880A1 (de)
DE (1) DE60038503T2 (de)
ES (1) ES2302707T3 (de)
GB (1) GB9930616D0 (de)
NZ (1) NZ519438A (de)
WO (1) WO2001047543A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
GB0116249D0 (en) * 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
JP2003055202A (ja) * 2001-08-15 2003-02-26 Hiroyuki Hanai 炎症性腸疾患の予防・治療剤
EP1512415A4 (de) * 2002-05-29 2005-11-09 Anges Mg Inc Decoy-zusammensetzung zur behandlung und prävention von entzündlichen erkrankungen
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor
WO2004027063A1 (en) * 2002-09-19 2004-04-01 Institut National De La Sante Et De La Recherche Medicale-Inserm Use of sirnas for gene silencing in antigen presenting cells
EP1641927B1 (de) * 2003-02-18 2015-07-08 Baylor College of Medicine Induzierte aktivierung in dendritischen zellen
JP2007515937A (ja) * 2003-05-08 2007-06-21 ベス イスラエル デアコネス メディカル センター インコーポレイティッド ＮＦ−κＢの調節機構
TWI487535B (zh) 2004-11-30 2015-06-11 Centocor Inc 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
AU2006262917A1 (en) * 2005-06-23 2007-01-04 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
WO2007033475A1 (en) * 2005-09-20 2007-03-29 London Health Sciences Centre Research Inc. THE USE OF siRNAs IN ORGAN STORAGE/REPERFUSION SOLUTIONS
ES2435775T3 (es) 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
CN101240271B (zh) * 2006-08-28 2012-08-29 长春华普生物技术有限公司 Toll样受体调节性寡核苷酸及其用途
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
EP2465511B1 (de) * 2006-10-19 2019-05-22 Baylor College Of Medicine Verfahren und Zusammensetzungen zur Erzeugung einer Immunreaktion mittels CD40-Induktion sowie Strukturerkennungsrezeptoren und Adapter davon
WO2008080195A1 (en) * 2006-12-29 2008-07-10 The University Of Queensland Compositions and methods for treating or preventing unwanted immune responses
CA2738031C (en) 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
EP2734240B1 (de) * 2011-07-18 2018-03-21 University Of Kentucky Research Foundation Schutz von zellen aus alu-rna-induzierter degeneration und inhibitoren zum schutz von zellen
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
EP3569253A1 (de) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Verfahren zur induktion von partieller apoptose mithilfe von caspasepolypeptiden
EP3043641B1 (de) * 2013-09-12 2019-09-11 Icahn School of Medicine at Mount Sinai Für ein fluoreszierendes protein spezifische t-zell-rezeptoren, transgene tiere und verfahren zur deren herstellung, isolierte t-zellen und verfahren zur verwendung
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
US20150342961A1 (en) * 2014-06-03 2015-12-03 Hai-Hui Xue Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US10420836B2 (en) 2015-10-08 2019-09-24 Emory University Methods of immunizing a subject and compositions related thereto
PE20220768A1 (es) 2019-05-31 2022-05-16 Janssen Pharmaceutica Nv Inhibidores de molecula pequena de quinasa inductora de nf-kb

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) * 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
AU650249B2 (en) 1989-11-03 1994-06-16 Immulogic Pharmaceutical Corporation A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5180818A (en) * 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
AU656544B2 (en) 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
WO1995031483A1 (en) 1994-05-13 1995-11-23 Eclagen Limited Improvements in or relating to peptide delivery
NZ290089A (en) 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
US5597898A (en) 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
WO1997001340A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal mast cell stabilizers
EP0779361A3 (de) 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Verkürzte Form von Kappa B Inhibitor-Protein, rekombinanter Herstellung und Verwendung
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
EP0960204A4 (de) * 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer Methoden und reagenzien zur genetischen immunisierung
WO1998006692A1 (en) 1996-08-12 1998-02-19 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
CA2263835C (en) * 1996-08-26 2012-02-21 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6924308B1 (en) 1997-07-30 2005-08-02 Howard L. Elford Therapeutic process for inhibiting NF-κB
US5952483A (en) 1997-07-31 1999-09-14 Smithkline Beecham Corporation Human IκB-β
EP0897009A3 (de) 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 Polypeptide
JPH1171278A (ja) * 1997-09-01 1999-03-16 Kanegafuchi Chem Ind Co Ltd 転写因子ＮＦ−κＢ活性化阻害剤
GB9719238D0 (en) 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US5965421A (en) 1997-11-26 1999-10-12 Human Genome Sciences, Inc. Human IRAK-2
EP1119618A2 (de) 1998-02-19 2001-08-01 Peter Bromley Stress-promoter-kontrolle der therapeutischen genen in gentherapie: zusammensetzungen und verfahren
AU754434B2 (en) * 1998-05-06 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Novel inhibitors of NF-kappaB activation
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1165144A2 (de) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Mit einem eigengen-wildtyp transduzierte dendritische zellen lösen starke antitumor immunantwort aus
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
GB0116249D0 (en) * 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods

Also Published As

Publication number Publication date
US7915009B2 (en) 2011-03-29
AU2206201A (en) 2001-07-09
WO2001047543A2 (en) 2001-07-05
US20080124322A1 (en) 2008-05-29
CN1254272C (zh) 2006-05-03
CN1817367A (zh) 2006-08-16
EP1244466B1 (de) 2008-04-02
CN100563707C (zh) 2009-12-02
JP2003518507A (ja) 2003-06-10
NZ519438A (en) 2004-03-26
ATE390929T1 (de) 2008-04-15
WO2001047543A3 (en) 2002-01-17
GB9930616D0 (en) 2000-02-16
DE60038503T2 (de) 2009-04-30
EP1852123A2 (de) 2007-11-07
EP1852123A3 (de) 2008-09-10
ES2302707T3 (es) 2008-08-01
US20030153518A1 (en) 2003-08-14
AU781496B2 (en) 2005-05-26
CA2394880A1 (en) 2001-07-05
CN1434718A (zh) 2003-08-06
EP1244466A2 (de) 2002-10-02

Similar Documents

Publication Publication Date Title
DE60038503D1 (de) AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER
ATE357511T1 (de) Dipeptidylpeptidasen
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20020348D0 (no) Peptid acceptor ligeringsmetoder
HK1130069A1 (en) Tumor antigen based on products of the tumor suppressor gene wt1 wt1
ES2114692T3 (es) Reaccion en ciclos magneticos.
DK1351703T3 (da) Anvendelse af et polypeptid omfattende det ekstracellulære domæne af IL-20RA og IL-20RB til behandling af inflammation
ATE287402T1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
ATE462006T1 (de) Isoform des vegfs
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
BG105018A (en) Poly(adp-ribose)polymerase gene
WO2001088124A3 (en) Method and reagent for the inhibition of erg
DK0845034T3 (da) Peptid med pronociceptive egenskaber
NZ292369A (en) Protein and coding sequence for ciita transcription activation domain and methods for identifying compounds inhibiting it and this inhibiting mhc class ii gene expression
NO20033921L (no) Inhibitor av monoaminopptak
ES2188545T3 (es) Polimeros que contienen aminoacidos basicos alcoxilados, concensados, y procedimiento para su obtencion.
TWI256720B (en) Semiconductor wafer identification
DK1275638T3 (da) Kombinationspræparat til behandling af immunologiske sygdomme
WO2003004678A3 (en) Novel receptors
WO2003031470A3 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
WO2002046378A3 (en) Alternative pol k nucleotide and amino acid sequence and methods for using
NZ511166A (en) Genes that increase the production of HMG-CoA reductase inhibitor, ML-236B
DE60033146D1 (de) Inhibitorprotein der transkriptionsaktivierung

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: FOXWELL, BRIAN, LONDON, GB

Inventor name: FELDMANN, MARC, LONDON, GB

8364 No opposition during term of opposition